Close

Halozyme Therapeutics (HALO) Appoints New COO

Go back to Halozyme Therapeutics (HALO) Appoints New COO

Halozyme Names Mark J. Gergen As Chief Operating Officer

September 1, 2016 9:01 AM EDT

SAN DIEGO, Sept. 1, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), an oncology biotech developing novel oncology and drug-delivery therapies, today named biotech veteran Mark J. Gergen as senior vice president and chief operating officer, reporting to Dr. Helen Torley, president and chief executive officer.

Gergen will be responsible for corporate development, including the management of Halozyme's proprietary ENHANZE platform collaborations and overseeing the global product teams responsible for planning the development and commercialization of Halozyme's oncology pipeline, including clinical operations and clinical collaborations.

"Mark brings a wealth of business... More